School of Paediatrics and Child Health, The University of Western Australia, 35 Stirling Highway, WA 6009, Perth, Australia.
Vaccine. 2011 Jul 18;29(32):5163-70. doi: 10.1016/j.vaccine.2011.05.035. Epub 2011 May 27.
In Australia the 7-valent pneumococcal conjugate vaccine (PCV7) is administered at 2, 4 and 6 months of age, with no booster dose. Information on bacterial carriage and the aetiology of recurrent acute otitis media (rAOM) after introduction of PCV7 using the 3+0 schedule is required to evaluate the potential impact of second generation pneumococcal vaccines. We found that 2-4 years after introduction of PCV7 in the National Immunisation Program, nontypeable Haemophilus influenzae (NTHi) was the predominant pathogen isolated from the nasopharynx and middle ear of children with a history of rAOM. Compared with healthy controls (n=81), NTHi and Streptococcus pneumoniae carriage rates were significantly higher in children with a history of rAOM (n=186) (19% vs. 56% p<0.0001 and 26% vs. 41%, p=0.02, respectively). Carriage of PCV7 pneumococcal serotypes was rare, whereas PCV7-related and non-PCV7 serotypes were isolated of 38% of cases and 24% of controls. Serotype 19A was the most common serotype isolated from the nasopharynx and middle ear and accounted for 36% (14/39) of total pneumococcal isolates with reduced susceptibility to cotrimoxazole. Of the 119 children carrying NTHi, 17% of isolates were β-lactamase positive. The scarcity of PCV7 serotypes in children with and without a history of rAOM indicates that the 3+0 PCV7 schedule is preventing carriage and rAOM from PCV7 serotypes. Introduction of new vaccines in Australia with increased pneumococcal serotype and pathogen coverage, including 19A and NTHi, should decrease the circulation of antibiotic-resistant bacteria and reduce the burden of rAOM.
在澳大利亚,7 价肺炎球菌结合疫苗(PCV7)在 2、4 和 6 个月大时接种,没有加强剂量。需要了解引入 PCV7 后使用 3+0 方案的细菌携带情况和复发性急性中耳炎(rAOM)的病因,以评估第二代肺炎球菌疫苗的潜在影响。我们发现,在国家免疫计划中引入 PCV7 2-4 年后,从中耳和鼻咽分离出的主要病原体是非典型流感嗜血杆菌(NTHi)。与健康对照组(n=81)相比,有 rAOM 病史的儿童中 NTHi 和肺炎链球菌的携带率明显更高(n=186)(19%比 56%,p<0.0001;26%比 41%,p=0.02)。PCV7 型肺炎球菌血清型的携带率很低,而 PCV7 相关和非 PCV7 血清型分别在 38%的病例和 24%的对照组中分离出来。血清型 19A 是从中耳和鼻咽分离出的最常见血清型,占总肺炎球菌分离株的 36%(14/39),对复方新诺明的敏感性降低。在携带 NTHi 的 119 名儿童中,17%的分离株为β-内酰胺酶阳性。有和没有 rAOM 病史的儿童中 PCV7 血清型的缺乏表明,3+0 PCV7 方案可预防 PCV7 血清型的携带和 rAOM。在澳大利亚引入具有更高肺炎球菌血清型和病原体覆盖率的新疫苗,包括 19A 和 NTHi,应可减少抗生素耐药菌的传播,并降低 rAOM 的负担。